• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Motus GI Holdings Inc.

    8/9/24 5:26:42 PM ET
    $MOTS
    Medical/Dental Instruments
    Health Care
    Get the next $MOTS alert in real time by email
    S-8 POS 1 forms-8pos.htm

     

    As filed with the Securities and Exchange Commission on August [9], 2024

     

    Registration No. 333-271080

    Registration No. 333-263940

    Registration No. 333-254344

    Registration No. 333-237476

    Registration No. 333-230506

    Registration No. 333-224003

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-271080

    Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-263940

    Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-254344

    Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-237476

    Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-230506

    Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-224003

     

    UNDER THE SECURITIES ACT OF 1933

     

     

    MOTUS GI HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware   81-4042793

    (State or other jurisdiction of

    incorporation or organization)

     

    (IRS Employer

    Identification No.)

     

    1301 East Broward Boulevard, 3rd Floor

    Ft. Lauderdale, FL 33301

    (Address of Principal Executive Offices, including Zip Code)

     

    Motus GI Holdings, Inc. 2016 Equity Incentive Plan and

    2016 Israeli Sub-Plan to the Motus GI Holdings, Inc. 2016 Equity Incentive Plan

    (Full titles of the plans)

     

    Jeff Varsalone

    1301 East Broward Boulevard, 3rd Floor

    Ft. Lauderdale, FL 33301

    (Name and address of agent for service)

     

    (954) 541-8000

    (Telephone number, including area code, of agent for service)

     

    With copies to:

     

    Steven M. Skolnick, Esq.

    Lowenstein Sandler LLP

    1251 Avenue of the Americas

    New York, New York 10020

    Telephone: (212) 262-6700

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
           
    Non-accelerated filer ☒   Smaller reporting company ☒
           
          Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    DEREGISTRATION OF SECURITIES

     

    These post-effective amendments (the “Post-Effective Amendments”) are being filed by Motus GI Holdings, Inc., a Delaware corporation (the “Company”), to remove from registration all shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), and any and all other securities of the Company remaining unissued and unsold under the following Registration Statements on Form S-8 (the “Registration Statements”) filed by the Company with the Securities and Exchange Commission (“SEC”):

     

      ● Registration Statement No. 333-271080, filed with the SEC on April 3, 2023, pertaining to the registration of an aggregate of 279,586 shares of Common Stock to be issued pursuant to the Motus GI Holdings, Inc. 2016 Equity Incentive Plan and 2016 Israeli Sub-Plan to the Motus GI Holdings, Inc. 2016 Equity Incentive Plan, as amended (the “2016 Plan”);
         
      ● Registration Statement No. 333-263940, filed with the SEC on March 29, 2022, pertaining to the registration of an aggregate of 2,903,016 shares of Common Stock to be issued pursuant to the 2016 Plan;
         
      ● Registration Statement No. 333-254344, filed with the SEC on March 16, 2021, pertaining to the registration of an aggregate of 1,936,339 shares of Common Stock to be issued pursuant to the 2016 Plan;
         
      ● Registration Statement No. 333-237476, filed with the SEC on March 30, 2020, pertaining to the registration of an aggregate of 1,728,665 shares of Common Stock to be issued pursuant to the 2016 Plan;
         
      ● Registration Statement No. 333-230506, filed with the SEC on March 26, 2019, pertaining to the registration of an aggregate of 1,286,409 shares of Common Stock to be issued pursuant to the 2016 Plan; and
         
      ● Registration Statement No. 333-224003, filed with the SEC on March 29, 2018, pertaining to the registration of an aggregate of 2,641,250 shares of Common Stock to be issued pursuant to the 2016 Plan.

     

    For ease of reference, all share numbers above are as stated in the Registration Statements, without giving pro forma effect to any adjustments, as applicable, for subsequent events such as stock splits occurring after the original filing dates of the respective Registration Statements.

     

    In accordance with undertakings made by the Company in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any and all securities of the Company that were registered for issuance that remain unsold at the termination of the offerings, the Company hereby removes from registration any and all securities of the Company registered but unsold under each of the Registration Statements. As a result of this deregistration, no securities remain registered for sale pursuant to the Registration Statements.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Ft. Lauderdale, FL, on August [9], 2024.

     

      MOTUS GI HOLDINGS, INC.
         
      By: /s/ Jeff Varsalone
      Name: Jeff Varsalone
      Title: President

     

    No other person is required to sign this Post-Effective Amendment No. 1 to the Registration Statements in reliance on Rule 478 of the Securities Act of 1933, as amended.

     

     

     

     

    Get the next $MOTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MOTS

    DatePrice TargetRatingAnalyst
    1/25/2023Buy → Neutral
    Ladenburg Thalmann
    More analyst ratings

    $MOTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update

      Successfully ramped up limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system; Doubled the number of active Pure-Vu System customers ordering disposable sleeves with 100% of onboarded customers using Pure-Vu independently Appointed well-known investment bank to identify and evaluate strategic alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value FORT LAUDERDALE, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (OTCQB:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the first q

      5/14/24 4:05:00 PM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

      Initiated limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system, including successful UGI procedures at several leading hospital systemsThe Company is engaged in the process to seek strategic partnerships aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder valueRecent exercise of certain outstanding warrants provided infusion of $2.7M in gross proceeds to the Company, which extended its cash runway into the fourth quarter of 2024 FORT LAUDERDALE, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes a

      3/18/24 4:05:00 PM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • EndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive Officer

      Aldrich's proven commercial, operational and leadership expertise helps position EndoSound for EVS launch and sustainable growth EndoSound™ Inc., a pioneering medical technology company dedicated to advancing patient care, is pleased to announce the appointment of Scott Aldrich Jr as Chief Executive Officer on February 1st, 2024. Mr Aldrich is joining EndoSound from MotusGI (NASDAQ:MOTS) where he served as Vice President of Commercial and Strategy. Stephen Steinberg MD will remain on the executive leadership team as Chief Medical Officer. Mr Aldrich brings operational and commercial leadership abilities paired with extensive experience in interventional gastroenterology and medical devi

      2/29/24 7:57:00 AM ET
      $MOTS
      Medical/Dental Instruments
      Health Care

    $MOTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Motus GI Holdings Inc.

      SC 13G/A - Motus GI Holdings, Inc. (0001686850) (Subject)

      11/14/24 4:22:34 PM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Motus GI Holdings Inc.

      SC 13G - Motus GI Holdings, Inc. (0001686850) (Subject)

      2/14/24 3:44:05 PM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Motus GI Holdings, Inc. (Amendment)

      SC 13G/A - Motus GI Holdings, Inc. (0001686850) (Subject)

      12/29/21 4:28:32 PM ET
      $MOTS
      Medical/Dental Instruments
      Health Care

    $MOTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Motus GI downgraded by Ladenburg Thalmann

      Ladenburg Thalmann downgraded Motus GI from Buy to Neutral

      1/25/23 9:38:23 AM ET
      $MOTS
      Medical/Dental Instruments
      Health Care

    $MOTS
    Financials

    Live finance-specific insights

    See more
    • Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update

      Successfully ramped up limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system; Doubled the number of active Pure-Vu System customers ordering disposable sleeves with 100% of onboarded customers using Pure-Vu independently Appointed well-known investment bank to identify and evaluate strategic alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value FORT LAUDERDALE, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (OTCQB:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the first q

      5/14/24 4:05:00 PM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • Motus GI Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

      The Company continues its exploration process to target strategic and financing alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder valueThe Company is actively supporting its existing installed customer base and pipeline opportunities in contracted health systems  The Company is advancing its development of Pure-Vu EVS Gastro, designed for Upper GI bleeding procedures, and expects submission to FDA by the end of 2023 FORT LAUDERDALE, Fla., March 31, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and e

      3/31/23 4:05:00 PM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • Motus GI Reports Third Quarter 2022 Financial Results and Provides Business Update

      Pure-Vu EVS approved for use at 25 hospitals since launch in March 2022, resulting in highest quarterly revenue reported in the Company's historyRecently named a Sole Source Supplier by the Department of Veteran's Affairs, with several VA medical centers executing new contracts for Pure-Vu EVS systems under this designationPresented positive clinical data in three abstracts at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting that further illustrate how Pure-Vu EVS is enabling physicians to significantly improve visualization during colonoscopy procedures across different settings and patient populations FORT LAUDERDALE, Fla., Nov. 14, 2022 (GLOBE NEWSW

      11/14/22 4:05:00 PM ET
      $MOTS
      Medical/Dental Instruments
      Health Care

    $MOTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Durbin Scott

      4 - Motus GI Holdings, Inc. (0001686850) (Issuer)

      3/13/24 4:05:19 PM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Nelson Sonja

      4 - Motus GI Holdings, Inc. (0001686850) (Issuer)

      3/13/24 8:03:48 AM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Pruden Gary J

      4 - Motus GI Holdings, Inc. (0001686850) (Issuer)

      3/13/24 8:02:41 AM ET
      $MOTS
      Medical/Dental Instruments
      Health Care

    $MOTS
    SEC Filings

    See more
    • SEC Form EFFECT filed by Motus GI Holdings Inc.

      EFFECT - Motus GI Holdings, Inc. (0001686850) (Filer)

      8/14/24 12:15:04 AM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Motus GI Holdings Inc.

      EFFECT - Motus GI Holdings, Inc. (0001686850) (Filer)

      8/14/24 12:15:07 AM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Motus GI Holdings Inc.

      EFFECT - Motus GI Holdings, Inc. (0001686850) (Filer)

      8/14/24 12:15:02 AM ET
      $MOTS
      Medical/Dental Instruments
      Health Care

    $MOTS
    Leadership Updates

    Live Leadership Updates

    See more
    • EndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive Officer

      Aldrich's proven commercial, operational and leadership expertise helps position EndoSound for EVS launch and sustainable growth EndoSound™ Inc., a pioneering medical technology company dedicated to advancing patient care, is pleased to announce the appointment of Scott Aldrich Jr as Chief Executive Officer on February 1st, 2024. Mr Aldrich is joining EndoSound from MotusGI (NASDAQ:MOTS) where he served as Vice President of Commercial and Strategy. Stephen Steinberg MD will remain on the executive leadership team as Chief Medical Officer. Mr Aldrich brings operational and commercial leadership abilities paired with extensive experience in interventional gastroenterology and medical devi

      2/29/24 7:57:00 AM ET
      $MOTS
      Medical/Dental Instruments
      Health Care
    • Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors

      FORT LAUDERDALE, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, announced the appointment of Scott Durbin to the Company's Board of Directors (the "Board"). Mr. Durbin has more than 25 years of executive leadership, finance and clinical development experience, including the execution of over $5 billion in financings and merger transactions. In addition, the Company announced that David Hochman and Darren Sherman, independent members of the Board, have stepped down from the Board due to time requirements of their roles as Chief Executive Offi

      9/6/23 5:00:42 PM ET
      $MOTS
      $OBIO
      Medical/Dental Instruments
      Health Care
      Medicinal Chemicals and Botanical Products
    • Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

      Bill Little, previously Chief Operating Officer (COO) of Neovasc, Inc. through its acquisition by Shockwave Medical in April 2023, will lead efforts to forge further strategic collaborations in newly created Executive Vice President (EVP) of Corporate Development and Strategy role Andrew Taylor joins as Chief Financial Officer (CFO) with over 20 years of CFO experience with emerging growth companies, the last 15 of which were spent in the medical device sector NEW HOPE, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-rewa

      6/7/23 8:30:00 AM ET
      $MOTS
      $OBIO
      Medical/Dental Instruments
      Health Care
      Medicinal Chemicals and Botanical Products